EP1150671B1 - Use of pyrethroid compounds to promote hair growth - Google Patents
Use of pyrethroid compounds to promote hair growth Download PDFInfo
- Publication number
- EP1150671B1 EP1150671B1 EP99965013A EP99965013A EP1150671B1 EP 1150671 B1 EP1150671 B1 EP 1150671B1 EP 99965013 A EP99965013 A EP 99965013A EP 99965013 A EP99965013 A EP 99965013A EP 1150671 B1 EP1150671 B1 EP 1150671B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- hair growth
- composition
- independently
- pyrethroid
- ethanol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
Definitions
- Alopecia areata is a non-scarring inflammatory hair loss disease that can affect men, women, and even children.
- the factors that activate the onset of alopecia and the mechanisms of its development are not well understood. It is characterized clinically by the sudden appearance of a round or oval patch of non-scarring and painless hair loss with spontaneous remissions and exacerbations (Weitzer, Am. Fam. Physician 41(4) :1197-1201 (1990)).
- the annual incidence of alopecia areata is approximately 2 per 10,000 population.
- RU 2004154 and RU 2028802 disclose the use of compositions containing the type II pyrethroid cypermethrin to treat insect infestation of sheep. These documents do not disclose the use of pyrethroids for promoting hair growth.
- FR 2659014 discloses a lotion for treatment of hair loss that includes a crude extract of the pyrethrum plant, along with other components of vegetable, mineral, and animal origin.
- the invention features use of a type II pyrethroid selected from the group comprising cypermethrin, deltamethrin, or fenvalerate for the preparation of a composition for promoting hair growth, including for the treatment of a human with an insufficient amount of hair or an insufficient rate of hair growth.
- the pyrethroid is administered topically.
- the pyrethroid can be administered to the scalp, face, chest, legs, and other regions of the body.
- the pyrethroid is provided in a composition, e.g., a pharmaceutically acceptable composition.
- the weight percent of the pyrethroid ranges from 0.005% to 5%; the weight percent of the pyrethroid ranges from 0.01% to 2%.
- the compound is administered at any point in a hair cycle, e.g., in the anagen (growth) phase of hair growth; in the telogen (resting) phase of hair growth; in the catagen (the period between the telogen phase and the anagen phase) phase of hair growth.
- a subject in need of hair growth promoting treatment may be identified; after administration of a pyrethroid compound, the effect of the administration on hair growth may be evaluated; the treatment can involve more than one administration, e.g., at least two, three, or four administrations, of the pyrethroid compound.
- the subject can be male or female that suffers from genetic pattern baldness; suffers from a hormonal disorder which decreases hair growth; has received a treatment, e.g., radiation, or chemotherapy, or a drug which inhibits hair growth; or has had a surgical procedure, e.g., skin graft, which is in need of hair growth.
- a treatment e.g., radiation, or chemotherapy, or a drug which inhibits hair growth
- a surgical procedure e.g., skin graft, which is in need of hair growth.
- the invention features the use of a compound of the formula: wherein R 1 is in which each of R a , R b , R c , and R d , independently, is H, fluoro, chloro, bromo, iodo, or C 1-4 alkyl.
- Alkyl can be either a straight or branched group. Some examples of alkyl groups are methyl, ethyl, propyl, isopropyl, butyl, isobutyl, and tert-butyl.
- R 2 is CN or C ⁇ CH; and R 3 is in which X is O, S, NH, or CH 2 ; and each of R' and R", independently, is H, fluoro, chloro, bromo, iodo, or C 1-4 alkyl.
- the compound can exist as a salt, e.g., a hydrochloride salt.
- the compound is administered topically.
- the compound can be administered to the scalp, face, chest, legs, and other regions of the body.
- the compound is provided in a composition, e.g., a pharmaceutically acceptable composition.
- the compound is administered at any point in a hair cycle, e.g., in the anagen (growth) phase of hair growth; in the telogen (resting) phase of hair growth; in the catagen (the period between the telogen phase and the anagen phase) phase of hair growth.
- R 2 is CN.
- R 1 is in which each of R a , R b and R c , independently, is H, fluoro, chloro, bromo, iodo, or C 1-4 alkyl.
- each of R a and R b independently, is chloro or bromo; and R c is H.
- each of R a and R b independently, is chloro; X is O; and each of R' and R", independently, is H.
- each of R a and R b independently, is bromo; X is O; and each of R' and R", independently, is H.
- R 1 is in which R d is H, fluoro, chloro, bromo, iodo, or C 1-4 alkyl.
- R d is chloro;
- X is O; and each of R' and R", independently, is H.
- X is O; each of R' and R", independently, is H.
- a subject in need of hair growth promoting treatment may be identified; after administration of the compound, the effect of the administration on hair growth may be evaluated; the treatment can involve more than one administration, e.g., at least two, three, or four administrations, of the compound.
- the subject can be male or female that suffers from genetic pattern baldness; suffers from a hormonal disorder which decreases hair growth; has received a treatment, e.g., radiation, or chemotherapy, or a drug which inhibits hair growth; or has had a surgical procedure, e.g., skin graft, which is in need of hair growth.
- a treatment e.g., radiation, or chemotherapy, or a drug which inhibits hair growth
- a surgical procedure e.g., skin graft, which is in need of hair growth.
- a composition for promoting hair growth includes the type II pyrethroid cypermethrin, deltamethrin, or fenvalerate, and a pharmaceutically acceptable carrier.
- the composition is sterile.
- the composition includes a fragrance.
- the weight percent of the pyrethroid in the composition ranges from 0.005% to 5%; the weight percent of the compound in the composition ranges from 0.01% to 2%.
- the compound is administered at any point in a hair cycle, e.g., in the anagen (growth) phase of hair growth; in the telogen (resting) phase of hair growth; in the catagen (the period between the telogen phase and the anagen phase) phase of hair growth.
- a kit for promoting hair growth includes, a compound described herein and instruction for use of the compound to promote hair growth.
- a container which includes a compound described herein has one or more of the following properties: it contains less than 5.0, 1.0, 0.5, or 0.1 g of the compound described herein; it is air tight; it is waterproof; or in addition to the compound described herein, it contains a fragrance or other cosmetic ingredient.
- promoting hair growth is meant an increase in the total mass of hair or the total length of the hairs, in a unit area, e.g., per cm 2 , as compared to nontreated tissue. It can include one or more of: an increase in the length or growth rate of a hair shaft, an increase in the number of hairs, or an increase in the thickness of a hair. In a preferred embodiment, the growth rate is increased.
- the invention relates to the use of specific pyrethroid Type II compounds, i.e., cypermethrin, deltamethrin or fenvalerate for the preparation of a composition for promoting hair growth.
- Type I pyrethroid compounds e.g., permethrin
- type II pyrethroid compounds e.g., cypermethrin
- type II compounds possess a cyano group on the ⁇ -carbon atom of the phenoxybenzyl moiety.
- Another aspect of this invention features the use of a composition having a compound of formula (I) as an active ingredient for the preparation of a composition for promoting hair growth.
- R 1 is in which each of R a , R b , R c , and R d , independently, is H, fluoro, chloro, bromo, iodo, or C 1-4 alkyl
- R 2 is CN or C ⁇ CH
- R 3 is in which X is O, S, NH, or CH 2
- each of R' and R" independently, is H, fluoro, chloro, bromo, iodo, or C 1-4 alkyl.
- the compounds described above exhibit geometrical and optical isomerism.
- geometrical isomerism can result from the configuration of different substituents on the cyclopropyl ring with respect to one another and the ring.
- Optical isomerism can arise from different arrangement of the substituents on the carbon atom attaching to the ⁇ -cyano or the ⁇ -ethynyl group.
- Both optically active and racemic mixtures of pyrethroid compounds (or their salts) can be employed in the composition of this invention.
- a pharmaceutical composition containing a compound described herein can be used to promote hair growth.
- the compositions can be used to treat alopecia (including androgenic alopecia, e.g., male pattern baldness, and alopecia areata).
- alopecia including androgenic alopecia, e.g., male pattern baldness, and alopecia areata.
- the use of such a composition for the manufacture of a medicament for promoting hair growth is also within the scope of this invention.
- Hair growth may be promoted by administering to a subject an effective amount of a compound described herein.
- An effective amount of the composition of the present invention is defined as the amount of the composition which, upon administration to an animal in need, confers a hair growth-promoting effect on treated animals.
- the effective amount to be administered to an animal is typically based on a variety of factors including age, sex, surface area, weight, and conditions of the animal. Body surface area may be approximately determined from height and weight of the patient. See, e.g., Scientific Tables, Geigy Pharmaceuticals, Ardley, New York, 1970, 537.
- An effective amount of a compound described herein in the composition of this invention i.e., doses, e.g., daily doses, can range from 0.01 mg/kg to 25 mg/kg; from 0.1 mg/kg to 12.5 mg/kg. Effective doses will also vary, as recognized by those skilled in the art, dependant on route of administration, excipient usage, and the possibility of co-usage with other treatments such as usage of other hair growth-promoting compounds.
- the pharmaceutical composition may be administered via the parenteral route, including orally, topically, subcutaneously, intraperitoneally, intramuscularly, intranasally, and intravenously. Topical administration is preferred. Repeated administration of the composition, e.g., repeated topical administration, can be used. More than one route of administration can be used simultaneously, e.g., topical administration in association with oral administration.
- parenteral dosage forms include aqueous solutions of the active agent, in a isotonic saline, 5% glucose or other well-known pharmaceutically acceptable excipient. Solubilizing agents such as cyclodextrins, or other solubilizing agents well-known to those familiar with the art, can be utilized as pharmaceutical excipients for delivery of the hair growth-promoting composition.
- composition of this invention can also be formulated into dosage forms for other routes of administration utilizing conventional methods.
- a pharmaceutical composition can be formulated, for example, in dosage forms for oral administration in a capsule, a tablet (each including timed release and sustained release formulations), or a gel seal.
- Capsules may comprise any standard pharmaceutically acceptable material such as gelatin or cellulose derivatives. Tablets may be formulated in accordance with the conventional procedure by compressing mixtures of pyrethroid compounds and a solid carrier, and a lubricant. Examples of solid carriers include starch and sugar bentonite.
- the hair growth-promoting composition can also be administered in a form of a hard shell tablet or capsule containing, for example, lactose or mannitol as a binder and a conventional filler and a tableting agent.
- Topical administration of the hair growth-promoting compounds described herein presents an attractive route of administration amongst the many different routes described above.
- Such topical pharmaceutical compositions can exist in many forms, e.g., in the form of a solution, cream, ointment, gel, lotion, shampoo, or aerosol formulation adapted for application to the skin.
- the weight percent of the active ingredient in the composition i.e., the pyrethroid compound, can be useful in promoting hair growth in ranges from 0.01% to 5% (based on the total weight of the composition) in admixture with a pharmaceutically acceptable carrier.
- a wide variety of carrier materials can be employed in the hair growth-promoting composition of this invention such as alcohols, aloe vera gel, allantoin, glycerine, vitamin A and E oils, mineral oils, and polyethylene glycols.
- Other additives e.g., fragrance or other cosmetic ingredients, can be present in the composition.
- the pyrethroid-containing compositions i.e., the compositions containing cypermethrin, deltamethrin, fenvalerate, or permethrin did not increase ear thickness when compared to ethanol. In other words, all four compositions tested did not have primary irritancy at a concentration of 1% in ethanol.
- TPA 12-O-tetradecanoyl-phorbol 13-acetate
- Example 1 As was seen in Example 1, the compositions tested failed to cause skin irritation, as compared to ethanol.
- compositions containing cypermethrin, deltamethrin, fenvalerate, and permethrin all failed to cause skin irritation (redness) with three repeated topical administration to mice skin at a concentration of 1% in ethanol.
- compositions containing cypermethrin, deltamethrin, and fenvalerate were effective in promoting hair growth. New hair growth occurred at areas of the skin where the compositions were applied.
- the hair growth-promoting compositions of the invention can contain two or more pyrethroid compounds.
Description
- Unwanted hair loss can plague both men and women of all ages. It can arise as the result of a variety of underlying causes, including hormonal imbalance, genetic predisposition and exposure to toxic substances. Alopecia areata is a non-scarring inflammatory hair loss disease that can affect men, women, and even children. The factors that activate the onset of alopecia and the mechanisms of its development are not well understood. It is characterized clinically by the sudden appearance of a round or oval patch of non-scarring and painless hair loss with spontaneous remissions and exacerbations (Weitzer, Am. Fam. Physician 41(4) :1197-1201 (1990)). The annual incidence of alopecia areata is approximately 2 per 10,000 population. 5% to 10% of patients, especially children, result in a total loss of all of the scalp hair (alopecia totalis). Although the disease itself is non-life threatening, the cosmetic and psychological impact on both patients and parents is tremendous. Patients usually suffer from a higher than normal rate of major depression and/or other anxiety disorder (Colon et al., Comprehensive Psychiatry 32 (3) : 245-251 (1991); Beard, J. Am. Acad. Dermatol. 14(4) : 697-700 (1986)).
- RU 2004154 and RU 2028802 disclose the use of compositions containing the type II pyrethroid cypermethrin to treat insect infestation of sheep. These documents do not disclose the use of pyrethroids for promoting hair growth.
- FR 2659014 discloses a lotion for treatment of hair loss that includes a crude extract of the pyrethrum plant, along with other components of vegetable, mineral, and animal origin.
- Naturstoffchemie (Nuhn, 1990) discloses that synthetic pyrethroids are chemically more stable than the active substances in the pyrethrum plant, natural pyrethrums.
- In general, the invention features use of a type II pyrethroid selected from the group comprising cypermethrin, deltamethrin, or fenvalerate for the preparation of a composition for promoting hair growth, including for the treatment of a human with an insufficient amount of hair or an insufficient rate of hair growth. In a preferred embodiment, the pyrethroid is administered topically. The pyrethroid can be administered to the scalp, face, chest, legs, and other regions of the body. In a preferred embodiment, the pyrethroid is provided in a composition, e.g., a pharmaceutically acceptable composition. In a preferred embodiment, the weight percent of the pyrethroid ranges from 0.005% to 5%; the weight percent of the pyrethroid ranges from 0.01% to 2%. In a preferred embodiment, the compound is administered at any point in a hair cycle, e.g., in the anagen (growth) phase of hair growth; in the telogen (resting) phase of hair growth; in the catagen (the period between the telogen phase and the anagen phase) phase of hair growth.
- A subject in need of hair growth promoting treatment may be identified; after administration of a pyrethroid compound, the effect of the administration on hair growth may be evaluated; the treatment can involve more than one administration, e.g., at least two, three, or four administrations, of the pyrethroid compound.
- In a preferred embodiment, the subject can be male or female that suffers from genetic pattern baldness; suffers from a hormonal disorder which decreases hair growth; has received a treatment, e.g., radiation, or chemotherapy, or a drug which inhibits hair growth; or has had a surgical procedure, e.g., skin graft, which is in need of hair growth.
- In another aspect, the invention features the use of a compound of the formula:
- In a preferred embodiment, the compound is administered topically. The compound can be administered to the scalp, face, chest, legs, and other regions of the body. In a preferred embodiment, the compound is provided in a composition, e.g., a pharmaceutically acceptable composition. In a preferred embodiment, the compound is administered at any point in a hair cycle, e.g., in the anagen (growth) phase of hair growth; in the telogen (resting) phase of hair growth; in the catagen (the period between the telogen phase and the anagen phase) phase of hair growth.
- In a preferred embodiment, R2 is CN. In a preferred embodiment, R1 is
- A subject in need of hair growth promoting treatment may be identified; after administration of the compound, the effect of the administration on hair growth may be evaluated; the treatment can involve more than one administration, e.g., at least two, three, or four administrations, of the compound.
- In a preferred embodiment, the subject can be male or female that suffers from genetic pattern baldness; suffers from a hormonal disorder which decreases hair growth; has received a treatment, e.g., radiation, or chemotherapy, or a drug which inhibits hair growth; or has had a surgical procedure, e.g., skin graft, which is in need of hair growth.
- A composition for promoting hair growth includes the type II pyrethroid cypermethrin, deltamethrin, or fenvalerate, and a pharmaceutically acceptable carrier. In a preferred embodiment, the composition is sterile. In a preferred embodiment, the composition includes a fragrance. In a preferred embodiment, the weight percent of the pyrethroid in the composition ranges from 0.005% to 5%; the weight percent of the compound in the composition ranges from 0.01% to 2%. In a preferred embodiment, the compound is administered at any point in a hair cycle, e.g., in the anagen (growth) phase of hair growth; in the telogen (resting) phase of hair growth; in the catagen (the period between the telogen phase and the anagen phase) phase of hair growth.
- A kit for promoting hair growth includes, a compound described herein and instruction for use of the compound to promote hair growth.
- A container which includes a compound described herein, has one or more of the following properties: it contains less than 5.0, 1.0, 0.5, or 0.1 g of the compound described herein; it is air tight; it is waterproof; or in addition to the compound described herein, it contains a fragrance or other cosmetic ingredient.
- By promoting hair growth is meant an increase in the total mass of hair or the total length of the hairs, in a unit area, e.g., per cm2, as compared to nontreated tissue. It can include one or more of: an increase in the length or growth rate of a hair shaft, an increase in the number of hairs, or an increase in the thickness of a hair. In a preferred embodiment, the growth rate is increased.
- Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, suitable methods and materials are described below. In addition, the materials, methods, and examples are illustrative.
- Other features or advantages of the present invention will be apparent from the following detailed description of several embodiments, and also from the appending claims.
- The invention relates to the use of specific pyrethroid Type II compounds, i.e., cypermethrin, deltamethrin or fenvalerate for the preparation of a composition for promoting hair growth. Type I pyrethroid compounds (e.g., permethrin) differ from type II pyrethroid compounds (e.g., cypermethrin) in that type II compounds possess a cyano group on the α-carbon atom of the phenoxybenzyl moiety.
- Another aspect of this invention features the use of a composition having a compound of formula (I) as an active ingredient for the preparation of a composition for promoting hair growth.
- The compounds described above can be synthesized according to procedures known in the art, e.g., by transesterification or Wittig reaction. A detailed description of the preparation of the pyrethroid compounds can be found in U.S. Patent No. 4,024,1ε3.
- A pharmaceutical composition containing a compound described herein can be used to promote hair growth. The compositions can be used to treat alopecia (including androgenic alopecia, e.g., male pattern baldness, and alopecia areata). The use of such a composition for the manufacture of a medicament for promoting hair growth is also within the scope of this invention.
- Hair growth may be promoted by administering to a subject an effective amount of a compound described herein.
- An effective amount of the composition of the present invention is defined as the amount of the composition which, upon administration to an animal in need, confers a hair growth-promoting effect on treated animals. The effective amount to be administered to an animal is typically based on a variety of factors including age, sex, surface area, weight, and conditions of the animal. Body surface area may be approximately determined from height and weight of the patient. See, e.g., Scientific Tables, Geigy Pharmaceuticals, Ardley, New York, 1970, 537. An effective amount of a compound described herein in the composition of this invention, i.e., doses, e.g., daily doses, can range from 0.01 mg/kg to 25 mg/kg; from 0.1 mg/kg to 12.5 mg/kg. Effective doses will also vary, as recognized by those skilled in the art, dependant on route of administration, excipient usage, and the possibility of co-usage with other treatments such as usage of other hair growth-promoting compounds.
- The pharmaceutical composition may be administered via the parenteral route, including orally, topically, subcutaneously, intraperitoneally, intramuscularly, intranasally, and intravenously. Topical administration is preferred. Repeated administration of the composition, e.g., repeated topical administration, can be used. More than one route of administration can be used simultaneously, e.g., topical administration in association with oral administration. Examples of parenteral dosage forms include aqueous solutions of the active agent, in a isotonic saline, 5% glucose or other well-known pharmaceutically acceptable excipient. Solubilizing agents such as cyclodextrins, or other solubilizing agents well-known to those familiar with the art, can be utilized as pharmaceutical excipients for delivery of the hair growth-promoting composition.
- The composition of this invention can also be formulated into dosage forms for other routes of administration utilizing conventional methods. A pharmaceutical composition can be formulated, for example, in dosage forms for oral administration in a capsule, a tablet (each including timed release and sustained release formulations), or a gel seal. Capsules may comprise any standard pharmaceutically acceptable material such as gelatin or cellulose derivatives. Tablets may be formulated in accordance with the conventional procedure by compressing mixtures of pyrethroid compounds and a solid carrier, and a lubricant. Examples of solid carriers include starch and sugar bentonite. The hair growth-promoting composition can also be administered in a form of a hard shell tablet or capsule containing, for example, lactose or mannitol as a binder and a conventional filler and a tableting agent.
- Topical administration of the hair growth-promoting compounds described herein presents an attractive route of administration amongst the many different routes described above. Such topical pharmaceutical compositions can exist in many forms, e.g., in the form of a solution, cream, ointment, gel, lotion, shampoo, or aerosol formulation adapted for application to the skin. The weight percent of the active ingredient in the composition, i.e., the pyrethroid compound, can be useful in promoting hair growth in ranges from 0.01% to 5% (based on the total weight of the composition) in admixture with a pharmaceutically acceptable carrier. A wide variety of carrier materials can be employed in the hair growth-promoting composition of this invention such as alcohols, aloe vera gel, allantoin, glycerine, vitamin A and E oils, mineral oils, and polyethylene glycols. Other additives, e.g., fragrance or other cosmetic ingredients, can be present in the composition.
- The following specific examples, which describe the hair growth-compositions of this invention and biological testings of such compositions, are to be construed as illustrative.
- The following example was performed to determine if pyrethroid compounds cause skin irritation (as indicated by ear thickness in mice). Skin irritants may contribute to promoting hair growth.
- Prior to the experiment, ear thickness of mice (C3H strain, female, 16 weeks of age, n = 3/group) was measured with a thickness gage (Mitsutoyo Corp.). After measuring ear thickness of both ears, 10 µL of ethanol was applied on left ear and 10 µL of a pyrethroid solution (1% pyrethroid compound in ethanol) was applied to the right ear. Ear thickness was measured for three consecutive days after administration. The results of left and right ear thickness are tabulated in Table 1 below:
Table 1 Left Ear day 0 1 2 3 Group I Ethanol only (x 0.01mm) 27.7 27.7 27.3 27.7 SD 0.58 0.58 0.58 1.15 Group II Ethanol only (x 0.01mm) 27.0 27.3 27.3 27.7 SD 0 0.58 0.58 0.58 Group III Ethanol only (x 0.01mm) 27.3 28.3 27.7 27.3 SD 0 1.15 1.15 0.58 Group IV Ethanol only (x 0.01mm) 27.3 27.7 27.3 28.0 SD 0.58 0.58 0.58 1.00 Right Ear day 0 1 2 3 Group I Cypermethrin (x 0.01mm) 27.7 27.7 27.3 28.0 SD 0.58 0.58 0.58 1.00 Group II Deltamethrin (x 0.01mm) 27.0 27.3 27.3 28.0 SD 0 0.58 0.58 1.00 Group III Fenvalerate (x 0.01mm) 27.3 28.0 28.0 27.0 SD 0.58 1.00 1.73 1.00 Group IV Permethrin (x 0.01mm) 27.3 27.7 27.7 28.3 SD 0.58 0.58 0.58 1.15 - As can be seen from Table 1 above, the pyrethroid-containing compositions, i.e., the compositions containing cypermethrin, deltamethrin, fenvalerate, or permethrin did not increase ear thickness when compared to ethanol. In other words, all four compositions tested did not have primary irritancy at a concentration of 1% in ethanol.
- Another ear thickness experiment was performed. Ear thickness of mice (Sencar strain, female, 10 weeks of age, n = 3/group) was measured with a thickness gage (Mitsutoyo Corp.). After measuring the thickness of both ears at the beginning of the experiment, 20 µL of 12-O-tetradecanoyl-phorbol 13-acetate (TPA) at a concentration of 10-4 M in acetone was applied on both ears, followed by the application of 10 µL of ethanol on the left ears and 10 µL of the four compositions tested in Example 1 on the right ears (at a concentration of 1% of pyrethroid compound in ethanol solution). Again, ear thickness was monitored over three consecutive days following administration of the compositions. The results are provide in Table 2.
Table 2 Left Ear day 0 1 2 3 Group I Ethanol only (x 0.01mm) 24.0 27.7 28.3 28.3 SD 1.00 28.0 2.52 1.53 Group II Ethanol only (x 0.01mm) 26.0 28.0 29.0 29.0 SD 2.65 0.58 2.00 1.73 Group III Ethanol only (x 0.01mm) 24.0 27.3 29.0 28.3 SD 0 1.53 1.00 0.58 Group IV Ethanol only (x 0.01mm) 23.7 29.7 27.7 28.0 SD 0.58 3.06 2.08 1.73 Right Ear day 0 1 2 3 Group I Cypermethrin (x 0.01mm) 24.0 26.7 28.3 27.3 SD 1.00 0.58 2.31 0.58 Group II Deltamethrin (x 0.01mm) 26.0 27.3 29.0 28.0 SD 2.65 0.58 2.00 1.73 Group III Fenvalerate (x 0.01mm) 24.0 26.3 26.7 26.7 SD 1.00 0.58 0.58 0.58 Group IV Permethrin (x 0.01mm) 23.3 27.3 27.0 27.7 SD 0.58 1.53 0 0.58 - As was seen in Example 1, the compositions tested failed to cause skin irritation, as compared to ethanol.
- This experiment was conducted to test the skin irritancy of the compositions of this invention on hair-growing areas of test subjects, i.e., female mice (10 weeks old) of the C3H strain (n = 5/group). After clipping the hair of the back skin of mice with an electric clipper, 5 µL/cm2 of each four composition tested in Examples 1 and 2 (at a concentration of 1% in an ethanol solution) were applied. The application was administered once a day, for 3 consecutive days. Skin irritation was evaluated by unaided visual inspection at the end of the third day. The level of irritation was scored as follows:
- -: no irritation
- ±: weak irritation
- +: clear irritation
- ++: strong irritation
- The results are presented in Table 3.
Table 3 Concentration after 72 hours Group I Cypermethrin 1% in ethanol - Group II Deltamethrin 1% in ethanol - Group III Fenvalerate 1% in ethanol - Group IV Permethrin 1% in ethanol - - Based on the results in Table 3, the four compositions, i.e., the compositions containing cypermethrin, deltamethrin, fenvalerate, and permethrin, all failed to cause skin irritation (redness) with three repeated topical administration to mice skin at a concentration of 1% in ethanol.
- The ability of topical administration of pyrethroid compounds to promote hair growth was assessed in female C3H strain mice (10 weeks old; n = 5/group). Hair on the back skin of the mice was clipped carefully with an electric clipper. 5 µL/cm2 of the five compositions tested in the examples above were applied to the mice daily. The level of hair growth at the applied skin areas were evaluated by unaided visual inspection at the indicated time. Cyclosporin A was used as a control. The results are shown in Table 4.
Table 4 Day 7 14 19 29 36 Group I Cypermethrin 1% 0 0 2 4 5 Ethanol 0 0 0 0 0 Group II Deltamethrin 1% 0 0 1 5 5 Ethanol 0 0 0 0 0 Group III Fenvalerate 1% 0 0 1 4 4 Ethanol 0 0 0 0 0 Group IV Permethrin 1% 0 0 0 0 0 Ethanol 0 0 0 0 0 Cyclosporin A 1% 0 5 5 5 5 Ethanol 0 0 0 0 0 - The results showed that the compositions containing cypermethrin, deltamethrin, and fenvalerate were effective in promoting hair growth. New hair growth occurred at areas of the skin where the compositions were applied.
- The experiment described in Example 4 was repeated with a commercially available hair growth-promoting compound (5% minoxidil) as a control. The results are shown in Table 5.
Table 5 Week 1 2 3 4 5 6 Group I Cypermethrin 1% 0 0 5 5 5 5 0.1% 0 0 5 5 5 5 0.01% 0 0 0 0 0 0 Ethanol 0 0 0 0 0 0 Group II Deltamethrin 1% 0 2 5 5 5 5 0.1% 0 0 5 5 5 5 0.01% 0 0 1 1 1 3 Ethanol 0 0 0 0 1 1 Group III Fenvalerate 1% 0 0* 3* 5 5 5 0.1% 0 0 5 5 5 5 0.01% 0 0 0 0 0 0 Ethanol 0 0 0 0 0 0 Group IV Permethrin 1% 0 0 0 0 0 1 0.1% 0 0 0 0 0 0 0.01% 0 0 0 0 0 0 Ethanol 0 0 0 0 0 0 Minoxidil 5% 0 0 2 3 4 4 Ethanol 0 0 0 0 0 0 * skin color of 2 out of 5 mice was lightened; no hair growth was observed at the indicated time period - The results above showed that the three compositions containing cypermethrin, deltamethrin, and fenvalerate were effective in promoting hair growth at concentrations of 0.1% and 1% in ethanol solutions. New hair growth occurred at areas of the skin where the compositions were applied. Moreover, the hair growth potency was dose dependent.
- From the above description, one skilled in the art can ascertain the essential characteristics of the present invention, and without departing from the spirit and scope thereof, can make various changes and modifications of the invention to adapt it to various usages and conditions. For example, the hair growth-promoting compositions of the invention can contain two or more pyrethroid compounds.
Claims (21)
- Use of a type II pyrethroid selected from cypermethrin, deltamethrin, or fenvalerate for the preparation of a composition for promoting hair growth.
- The use of claim 1, wherein the composition is to be administered topically.
- The use of claim 1 or 2, wherein the composition is sterile.
- The use of claim 3, wherein the weight percent of the pyrethroid in the composition ranges from 0.005% to 5%.
- The use of claim 4, wherein the weight percent of the pyrethroid in the composition ranges from 0.01 % to 2%.
- Use of a compound of the formula:
R1 is
R2 is CN or C≡CH, and
R3 is
or a salt thereof for the preparation of a composition for promoting hair growth. - The use of claim 6, wherein said composition is to be administered topically.
- The use of claim 6 or 7, wherein said composition is sterile.
- The use of claim 6, wherein R2 is CN.
- The use of claim 10, wherein each of Ra and Rb, independently, is chloro or bromo; and Rc is H.
- The use of claim 11, wherein each of Ra and Rb, independently, is chloro.
- The use of claim 12, wherein X is O; and each of R' and R", independently, is H.
- The use of claim 11, wherein each of Ra and Rb, independently, is bromo.
- The use of claim 14, wherein X is O; and each of R' and R", independently, is H.
- The use of claim 16, wherein Rd is chloro.
- The use of claim 17, wherein X is O; and each of R' and R", independently, is H.
- The use of claim 9, wherein X is O.
- The use of claim 19, wherein each of R' and R", independently, is H.
- The use of any of the preceding claims, wherein the composition further comprises a fragrance.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10917198P | 1998-11-20 | 1998-11-20 | |
US109171P | 1998-11-20 | ||
PCT/US1999/027585 WO2000030636A1 (en) | 1998-11-20 | 1999-11-19 | Use of pyrethroid compounds to promote hair growth |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1150671A1 EP1150671A1 (en) | 2001-11-07 |
EP1150671A4 EP1150671A4 (en) | 2004-08-04 |
EP1150671B1 true EP1150671B1 (en) | 2007-02-28 |
Family
ID=22326188
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99965013A Expired - Lifetime EP1150671B1 (en) | 1998-11-20 | 1999-11-19 | Use of pyrethroid compounds to promote hair growth |
Country Status (5)
Country | Link |
---|---|
US (2) | US6288112B1 (en) |
EP (1) | EP1150671B1 (en) |
JP (1) | JP2002530332A (en) |
DE (1) | DE69935350T2 (en) |
WO (1) | WO2000030636A1 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005514411A (en) * | 2002-01-10 | 2005-05-19 | ノバルティス アクチエンゲゼルシャフト | Drug delivery system for the prevention and treatment of vascular diseases comprising rapamycin and its derivatives |
JP2009084271A (en) * | 2007-09-07 | 2009-04-23 | Toyama Univ | Inducer for expression of brain-derived neurotrophic factor and method of inducing expression |
US20140212441A1 (en) * | 2011-06-21 | 2014-07-31 | R-Tech Ueno, Ltd. | Pharmaceutical composition for inflammatory diseases, allergic diseases and autoimmune diseases |
JP2015078128A (en) * | 2012-01-25 | 2015-04-23 | 学校法人東海大学 | Hair tonic |
US8921303B1 (en) | 2014-01-28 | 2014-12-30 | Avon Products, Inc. | Extended release fragrance compositions |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS515450B1 (en) | 1971-06-29 | 1976-02-20 | ||
US4024163A (en) | 1972-05-25 | 1977-05-17 | National Research Development Corporation | Insecticides |
CH679119A5 (en) | 1988-05-13 | 1991-12-31 | Sandoz Ag | |
FR2659014B1 (en) * | 1990-03-05 | 1993-10-15 | Gustave Mathieu | HAIR LOTION FOR STOPPING FALLING AND HAIR GROWTH COMPOSED OF PLANTS, MINERALS, ANIMALS IN THE FORM OF HOMEOPATIC DILUTIONS. |
RU2028802C1 (en) * | 1991-12-13 | 1995-02-20 | Волгоградское производственное объединение "Химпром" им.С.М.Кирова | Composition for treatment of sheep with estrosis |
RU2004154C1 (en) * | 1991-12-13 | 1993-12-15 | Волгоградское производственное объединение "Химпром" им.С.М.Кирова | Remedy for treating estrosis in sheep |
US5567704A (en) * | 1992-03-04 | 1996-10-22 | Cell Therapeutics, Inc. | R-enatiomerically pure hydroxylated xanthine compounds to treat baldness |
TW382595B (en) | 1993-10-15 | 2000-02-21 | Merck & Co Inc | Pharmaceutical composition for use in arresting and reversing androgenic alopecia |
AU715843B2 (en) * | 1994-11-28 | 2000-02-10 | Laboratoires Virbac | Residual control of parasites by long-acting shampoo formulations |
-
1999
- 1999-11-19 EP EP99965013A patent/EP1150671B1/en not_active Expired - Lifetime
- 1999-11-19 DE DE69935350T patent/DE69935350T2/en not_active Expired - Fee Related
- 1999-11-19 JP JP2000583519A patent/JP2002530332A/en active Pending
- 1999-11-19 US US09/444,420 patent/US6288112B1/en not_active Expired - Fee Related
- 1999-11-19 WO PCT/US1999/027585 patent/WO2000030636A1/en active IP Right Grant
-
2001
- 2001-05-16 US US09/858,929 patent/US20010027213A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
DE69935350T2 (en) | 2007-11-22 |
EP1150671A4 (en) | 2004-08-04 |
JP2002530332A (en) | 2002-09-17 |
US20010027213A1 (en) | 2001-10-04 |
US6288112B1 (en) | 2001-09-11 |
EP1150671A1 (en) | 2001-11-07 |
WO2000030636A1 (en) | 2000-06-02 |
DE69935350D1 (en) | 2007-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6420352B1 (en) | Hair loss prevention | |
KR100523503B1 (en) | Method of Treating Hair Loss Using Thyromimetic Compounds | |
MXPA00001000A (en) | A hair lotion with improved properties in its hair protecting action and prevention of hair loss, and the reduction of external effects of androgenic alopecia and resulting hair loss. | |
KR101330889B1 (en) | Composition for prevention of losing hair or promotion of growing hair | |
JP2937446B2 (en) | Blackening agent to prevent gray hair | |
US6465514B1 (en) | Methods and compositions for the promotion of hair growth | |
HU225475B1 (en) | Nicotinamide- and nicotinic acid ester salts for use in therapy and cosmetology, pharmaceutical and cosmetic compositions containing them, and use of nicotinamide-, nicotinic acid- and... | |
EP1150671B1 (en) | Use of pyrethroid compounds to promote hair growth | |
US5637606A (en) | Hair grower based on allantoin or derivatives thereof | |
KR20160029769A (en) | Cosmetic or pharmaceutical composition for promoting hair growth containing Hydroxydecanoic acid | |
US4520132A (en) | Use of undecylenic acid to treat herpes labialis | |
JP4032246B2 (en) | White hair prevention and improvement agent | |
KR20000053859A (en) | The hair-growing agent composition which is contained the extract from natural phellinus linteus and preparation method using the same | |
JP2002080327A (en) | Hair grower | |
US20060052405A1 (en) | Hair loss prevention | |
JP2546813B2 (en) | Hair nourishing cosmetics | |
JPH10279437A (en) | Hair cosmetic | |
KR101321045B1 (en) | Composition of preventing hair loss and promoting hair growth | |
USRE32990E (en) | Use of undercylenic acid to treat herpes labialis | |
JP2001131025A (en) | Cosmetic for scalp and hair | |
KR102386651B1 (en) | Composition for preventing or treating hair loss comprising tiplaxtinin | |
US20070292527A1 (en) | Composition for the cosmetic treatment of age-related dermatological symptoms | |
JPH11302131A (en) | Cosmetic for scalp and hair | |
US6187815B1 (en) | Methods and compositions for the promotion of hair growth | |
KR102611504B1 (en) | Composition for promoting the hair growth comprising kirenol |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20010521 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
RBV | Designated contracting states (corrected) |
Designated state(s): DE FR GB IT |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: 7A 61P 17/14 B Ipc: 7A 61K 31/215 A |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20040622 |
|
17Q | First examination report despatched |
Effective date: 20050509 |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): DE FR GB IT |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 69935350 Country of ref document: DE Date of ref document: 20070412 Kind code of ref document: P |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
26N | No opposition filed |
Effective date: 20071129 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20071127 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: GB Payment date: 20071128 Year of fee payment: 9 Ref country code: FR Payment date: 20071119 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20071221 Year of fee payment: 9 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20081119 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081119 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20090731 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20090603 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081119 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20081130 |